Advertisement

Breast Cancer Research and Treatment

, Volume 140, Issue 2, pp 307–316 | Cite as

The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer

  • Hany Onsy Habashy
  • Emad A. Rakha
  • Ian O. EllisEmail author
  • Desmond G. Powe
Preclinical study

Abstract

The coactivator-associated arginine methyltransferase-1 (CARM1) is implicated in regulation of oestrogen receptor (ER) α-mediated gene pathways in response to ER activation. It plays an important role in breast cancer growth by regulating the E2F1 expression suggesting that CARM1 could be a target in the subclassification of oestrogen-dependent breast cancer. This study aims to investigate the clinical and biological importance of CARM1 protein expression in a large (1,130 patients), well-characterised and annotated series of invasive breast cancers using tissue microarrays and immunohistochemistry. In the whole series, increased CARM1 expression is correlated with features associated with aggressive behaviour such as young age, premenopausal status, large tumour size and high tumour grade. There is a positive correlation between CARM1 expression and biomarkers associated with non-luminal phenotype and poor prognosis such as HER2, basal cytokeratins, EGFR, p53 and the proliferation markers Ki67, TK1, CD71 and Cyclin E. Negative associations with the luminal-associated markers including steroid receptors and luminal cytokeratins are found. Similar associations are identified in the ER-positive/luminal subgroup (n = 767). Outcome analyses indicate that CARM1 expression is an independent predictor of shorter breast cancer-specific survival and disease-free interval in the whole series and in the ER-positive subgroup. CARM1 shows an oncogenic effect in breast cancer and its expression is associated with poor prognosis. CARM1 could be a potential marker of luminal class subclassification and for target therapy, particularly in the ER-positive luminal-like subgroup.

Keywords

Breast carcinoma CARM1 Oestrogen receptor Prognosis Immunohistochemistry Coactivators 

Notes

Acknowledgments

We thank the ministry of higher education and Mansoura University (Egypt) for funding HO Habashy. Funding (salaries and infrastructure) was provided by the University of Nottingham and Nottingham University Hospitals NHS Trust.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Leo C, Chen JD (2000) The SRC family of nuclear receptor coactivators. Gene 245(1):1–11PubMedCrossRefGoogle Scholar
  2. 2.
    Onate SA, Boonyaratanakornkit V, Spencer TE, Tsai SY, Tsai M-J, Edwards DP et al (1998) The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem 273(20):12101–12108PubMedCrossRefGoogle Scholar
  3. 3.
    Miao F, Li S, Chavez V, Lanting L, Natarajan R (2006) Coactivator-associated arginine methyltransferase-1 enhances nuclear factor-{kappa}B-mediated gene transcription through methylation of histone H3 at Arginine 17. Mol Endocrinol 20(7):1562–1573PubMedCrossRefGoogle Scholar
  4. 4.
    Schurter BT, Koh SS, Chen D, Bunick GJ, Harp JM, Hanson BL, et al. (2001) Methylation of histone H3 by coactivator-associated arginine methyltransferase 1â€. Biochemistry 40(19):5747–5756Google Scholar
  5. 5.
    Stallcup MR, Kim JH, Teyssier C, Lee Y-H, Ma H, Chen D (2003) The roles of protein–protein interactions and protein methylation in transcriptional activation by nuclear receptors and their coactivators. J Steroid Biochem Mol Biol 85(2–5):139–145PubMedCrossRefGoogle Scholar
  6. 6.
    Frietze S, Lupien M, Silver PA, Brown M (2008) CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. Cancer Res 68(1):301–306PubMedCrossRefGoogle Scholar
  7. 7.
    An W, Kim J, Roeder RG (2004) Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 117(6):735–748PubMedCrossRefGoogle Scholar
  8. 8.
    Covic M, Hassa PO, Saccani S, Buerki C, Meier NI, Lombardi C et al (2005) Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-kappa B-dependent gene expression. EMBO J 24(1):85–96PubMedCrossRefGoogle Scholar
  9. 9.
    Hong H, Kao C, Jeng M-H, Eble JN, Koch MO, Gardner TA et al (2004) Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer 101(1):83–89PubMedCrossRefGoogle Scholar
  10. 10.
    El-Rehim DMA, Ball G, Pinder SE, Rakha E, Paish C, Robertson JFR et al (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340–350CrossRefGoogle Scholar
  11. 11.
    Elston CW, Ellis IO (1991) Pathological prognostic factors in breast-cancer.1. The value of histological grade in breast-cancer–experience from a large study with long-term follow-up. Histopathology 19(5):403–410PubMedCrossRefGoogle Scholar
  12. 12.
    Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham prognostic index in primary breast-cancer. Breast Cancer Res Treat 22(3):207–219PubMedCrossRefGoogle Scholar
  13. 13.
    Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J et al (2008) Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer 44(11):1541–1551PubMedCrossRefGoogle Scholar
  14. 14.
    McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS (1985) Estrogen-receptor analyses–correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109(8):716–721PubMedGoogle Scholar
  15. 15.
    Habashy H, Powe D, Rakha E, Ball G, Macmillan R, Green A, et al. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat 120(3):603-612Google Scholar
  16. 16.
    Camp RL, Dolled-Filhart M, Rimm DL (2004) X-Tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21):7252–7259PubMedCrossRefGoogle Scholar
  17. 17.
    McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229–235PubMedCrossRefGoogle Scholar
  18. 18.
    El-Rehim DMA, Pinder SE, Paish CE, Bell J, Blamey R, Robertson JFR et al (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203(2):661–671CrossRefGoogle Scholar
  19. 19.
    Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCrossRefGoogle Scholar
  20. 20.
    Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100(18):10393–10398PubMedCrossRefGoogle Scholar
  21. 21.
    Sorlie T, Perou CM, Fan C, Geisler S, Aas T, Nobel A et al (2006) Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 5(11):2914–2918PubMedCrossRefGoogle Scholar
  22. 22.
    Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98(19):10869–10874PubMedCrossRefGoogle Scholar
  23. 23.
    Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418–8423PubMedCrossRefGoogle Scholar
  24. 24.
    Ahr A, Holtrich U, Solbach C, Scharl A, Strebhardt K, Karn T et al (2001) Gene expression profiling for molecular identification of high-risk breast cancer patients. Geburtshilfe Frauenheilkd 61(12):954–963CrossRefGoogle Scholar
  25. 25.
    Mann M, Cortez V, Vadlamudi R (2013) PELP1 oncogenic functions involve CARM1 regulation. CarcinogenesisGoogle Scholar
  26. 26.
    El Messaoudi S, Fabbrizio E, Rodriguez C, Chuchana P, Fauquier L, Cheng DH et al (2006) Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proc Natl Acad Sci USA 103(36):13351–13356PubMedCrossRefGoogle Scholar
  27. 27.
    Burstein HJ (2005) The distinctive nature of HER2-positive breast cancers. N Engl J Med 353(16):1652–1654PubMedCrossRefGoogle Scholar
  28. 28.
    Davis MB, Liu X, Wang S, Reeves J, Khramtsov A, Huo D, Olopade OI (2013) Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity. Mol Cancer 12(1):40 Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Hany Onsy Habashy
    • 1
    • 2
  • Emad A. Rakha
    • 1
  • Ian O. Ellis
    • 1
    Email author
  • Desmond G. Powe
    • 1
    • 3
  1. 1.Department of HistopathologyNottingham City Hospital, School of Molecular Medical Sciences, The University of Nottingham and Nottingham University Hospitals NHS TrustNottinghamUK
  2. 2.Department of PathologyFaculty of Medicine, Mansoura UniversityMansouraEgypt
  3. 3.The John van Geest Cancer Research CentreNottingham Trent UniversityNottinghamUK

Personalised recommendations